Feedback plc (AIM: FDBK, “Feedback” or the “Company”), the specialist medical imaging technology company, announces that its operating company Feedback Medical Ltd has received its first order via GE Healthcare (GEHC) for TexRAD®, its patented image texture analysis technology.
The order follows the distribution agreement announced on 25 April 2018, granting GEHC non-exclusive global rights to offer TexRAD® for medical imaging research applications.
The TexRAD® software purchase is for the Post Graduate Institute of Medical Education & Research, Chandigarh, India. TexRAD® software is currently used in over 50 of the world’s leading research institutions across Europe, North America, Asia and Australasia. This expansion of sales and customer engagement in India via GEHC builds on Feedback’s existing strong customer base.
Dr Balaji Ganeshan, Global Business Development Director of Feedback Medical Ltd, said:
“This first purchase order of TexRAD® via GE Healthcare represents an important milestone in our business relationship and will help to grow our international reputation That one of India’s leading medical institutions has selected TexRAD® against other image analysis candidates is a strong endorsement of our technology.”
About Feedback plc
Feedback plc is a specialist medical imaging technology company. It develops software and systems that provide innovative techniques and improved workflows for practitioners involved in medical research and treating patients. TexRAD®, the Company’s patented quantitative image texture analysis technology, has the potential to assist clinicians in diagnosis, prognosis and treatment of patients with cancer and is currently installed in over 50 of the world’s leading research institutions across Europe, North America, Asia and Australasia. The Cadran platform provides a suite of medical imaging tools for decision support. The Cadran range includes the picture archiving communication system (PACS) to provide decision support for scan analysis, diagnostic workstations which provide secure remote access to view scans on demand, and products to securely share and transport patient data. Visit www.fbk.com.
About TexRAD® technology
TexRAD® is the Company’s patented quantitative image texture analysis technology for diagnostic radiological scans. The technology has the potential to assist clinicians in diagnosis, prognosis and treatment of patients with cancer, or other disease indications, and is currently installed in over 50 of the world’s leading research institutions across Europe, North America, Asia and Australasia. By analysing the texture features in computerised tomography (CT) scans, magnetic resonance images (MRI) and positron emission tomography scans (PET/CT), TexRAD’s quantitative imaging capabilities provide clinicians with additional, visually imperceptible information to make better decisions in order to improve patient outcomes.
TexRAD® research to date has shown great potential in many different oncological and non-oncological sites. For example, papers presented at RSNA 2017 focused on liver, pancreatic, kidney, cervical, oral, genitourinary, head & neck, thyroid, neuroendocrine and endometrial cancers, as well as gastrointestinal stromal tumours, gliomas, thymic-epithelial neoplasms and carotid-plaques. On 20 November 2017, Feedback announced the CE marked release of TexRAD® Lung, a “software only” Class 1 medical device, to help advance lung cancer diagnosis. Further information on the TexRAD® technology can be found at www.fbk.com.
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned